Abbott LaboratoriesABTNYSE
Loading
A large-scale business, with solid profitability priced at a premium.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Comprehensive financial statement data for deep analysis
| Metric | Dec 21 | Dec 22 | Dec 23 | Dec 24 | Dec 25 |
|---|---|---|---|---|---|
| Return on Equity | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - |
| Gross Margin | 53.9% | 51.1%↓5.1% | 50.0%↓2.3% | 50.8%↑1.8% | 55.5%↑9.2% |
| Operating Margin | 21.4% | 19.2%↓10.3% | 16.0%↓16.2% | 16.3%↑1.4% | 18.2%↑11.6% |
| Net Margin | 16.4% | 15.9%↓3.2% | 14.3%↓10.2% | 31.9%↑123.9% | 14.7%↓53.9% |
| Earnings Yield | - | - | - | - | - |